Randomised controlled trials (RCTs) are often costly, slow, and logistically challenging - ChatGPT (2025)
✅ 1. Pragmatic Clinical Trials (PCTs)
-
What: Conducted in real-world settings with broad patient inclusion criteria.
-
Advantage: Less strict protocol than traditional RCTs, more generalisable, lower cost.
-
Use Case: E.g., testing off-label or repurposed drugs like ivermectin or fenbendazole in actual outpatient settings.
✅ 2. N-of-1 Trials
-
What: A single patient undergoes multiple treatment periods with different therapies in random order.
-
Advantage: Useful for rare diseases or personalised treatment; faster and cheaper than large trials.
-
Use Case: Individualised testing for patients unresponsive to standard cancer therapies.
✅ 3. Synthetic Control Arms
-
What: Use historical data or real-world evidence (RWE) to replace or supplement the control group.
-
Advantage: Reduces need to randomise patients to placebo; saves time, money, and ethical concerns.
-
Use Case: Oncology studies where standard-of-care is already well documented.
✅ 4. Real-World Evidence (RWE) from Observational Studies
-
What: Retrospective or prospective cohorts using EMRs, patient registries, claims data, etc.
-
Advantage: Large, inexpensive data sets reflecting everyday practice; valuable especially when RCTs are not feasible.
-
Use Case: Evaluating long-term effects or safety profiles of interventions already in use.
✅ 5. Case Series / Retrospective Case Reviews
-
What: Compile and analyse existing anecdotal or clinical case data.
-
Advantage: Fast, useful for hypothesis generation or rare outcomes.
-
Use Case: Early-stage evaluation of repurposed or natural treatments in cancer (e.g. fenbendazole and ivermectin projects).
✅ 6. Bayesian Adaptive Trials
-
What: Uses Bayesian statistics to continuously update probability of treatment effect as data accumulates.
-
Advantage: More efficient, allows for early stopping or arm-dropping; flexible.
-
Use Case: Small-scale oncology studies where multiple treatment arms are tested.
✅ 7. Digital Trials / Remote Monitoring
-
What: Use apps, wearables, and telemedicine to gather patient-reported outcomes and data.
-
Advantage: Reduces infrastructure cost, improves scalability, improves compliance.
-
Use Case: Lifestyle or dietary interventions; long-term safety/effectiveness follow-ups.
8. In Silico (Computer Simulated) Randomised Controlled Trials
- Artificial intelligence—especially through in silico trials and causal modeling—can simulate trial arms, optimize patient recruitment, and predict outcomes, potentially accelerating trial design and reducing costs.
- By leveraging AI for simulation and prediction, researchers can better design trials, improve efficiency, and augment traditional clinical methods, ultimately bringing effective therapies to patients faster without compromising scientific rigor.
🔁 Hybrid Strategy Recommendation:
For controversial or off-label interventions (e.g. repurposed drugs, supplements), a retrospective case series → matched cohort from real-world data → pragmatic or adaptive trial pathway offers progressive evidence-building without jumping straight into a multi-million dollar RCT.A meta-analysis of meta-analyses
The faithful followers of mainstream medicine, and thus indirectly of the big pharmaceutical industry, who understand something about statistics, have been parroting throughout the COVID pandemic that the vast majority of studies on cheap treatments such as ivermectin, hydroxychloroquine, vitamin D, melatonin, zinc and others are observational, i.e. non-randomized controlled studies, and therefore have a built-in defect and can only detect correlation (association), but not causation. In other words, they have no value in public health.
For example, if ivermectin was given to one group of patients, and another group of patients refused or were unable to receive it, and if the ivermectin group had a significantly lower mortality rate, even if the results were adjusted for many baseline parameters, it could not be concluded that ivermectin was the one that reduced mortality because the patients in the groups were not randomly selected in advance (randomized). While this is potentially a valid argument, rejecting observational studies a priori is, to put it mildly, wrong. What is the contribution of c19early.org to this issue? They decided to test the hypothesis: do the pooled effects of randomized studies differ statistically significanly from the pooled effects of non-randomized studies? If there is a statistically significant difference between them, then, in general, it is most likely due to the unequal baseline characteristics of the treated and untreated groups in non-randomized studies.
Can you guess what their result was? I couldn’t believe it either when I looked at the so-called forest plot of the mega meta-analysis of 102 meta-analyses. The result in their own words:
“For the 102 treatments we cover, there is no difference in results between RCTs & observational studies, RR 1.00 [0.92-1.08].
For the subgroup of high-profit treatments, there is a non-significant trend towards greater efficacy in RCTs. This may be related to financial conflicts of interest.”
By the way, this is not the first meta-analysis of meta-analyses to compare randomized and non-randomized trials. In 2014, Engelmayer et al. published a Cochrane review/meta-analysis of 15 reviews that included 1583 meta-analyses for 228 different medical conditions with an average of 178 studies per paper.
A Revealing Look at Research Barriers and Narrative Influence
- Approval requirements reshaped which therapies reached trials — Early trial proposals were rejected until researchers could produce specific laboratory antiviral data for ivermectin, even though the broader protocol involved multiple licensed medications. The result? Ivermectin was removed from the proposed study just so the trial could move forward. In other words, administrative criteria — not clinical reasoning — determined which treatment strategies advanced and which ones the public never heard about.
- Research delays determined which treatments gained attention — While trial approvals stalled, public health policy moved quickly, opening a widening gap between early therapeutic ideas and the formal evidence needed to support them. This matters because when research starts late, the narrative gravitates toward whichever evidence appears first — not necessarily the best ideas initially explored. What you heard about reflected timing as much as scientific breadth.
- Combination strategies struggled inside single-drug frameworks — This is a key point. Regulatory frameworks frequently evaluate each drug component separately, even when the entire therapeutic hypothesis depends on synergy — multiple drugs working together to produce a stronger effect than any single one alone. Imagine testing whether a key works by examining the key and the lock in separate rooms — you'd never discover they fit together. That's essentially what happened when combination protocols were forced through a system designed to assess one drug at a time. The mismatch explains why biologically plausible strategies sometimes vanished from headlines despite having a clear rationale behind them.
- Funding direction accelerated some pathways while slowing others — Once major trials and funding streams locked in on specific approaches — antivirals and injections chief among them — alternative strategies received less attention, fewer resources, and slower evidence accumulation. This created a self-reinforcing cycle: heavily funded pathways generated more data, which reinforced their prominence in guidelines and media coverage. If you've ever wondered why consensus seems to develop unevenly across competing medical ideas, this is a large part of the reason.
Comments
Post a Comment